RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

I've been refraining from commenting on this topic up to this point, since most of the contributions have fallen under the Unshakeable Opinion umbrella. However, there is a fundamental element missing from this discussion:

Since Nuclear Winter began last...last fall, 'winter' began in autumn... how many licensing deals have small CNS companies been able to sign? Let's see: Torrey Pines sold its Alzheimer's research lock-stock-and-barrel to Eisai for....I believe the figure was about $1 million. And they sold off the remains of the Axonyx IP to Cenomed for....I don't believe it's been disclosed, but in fact there may not have been much if any upfront money at all. Evotec and Boehringer Ingelheim signed a joint research deal, but those two German companies had history from Evotec's service provider days. Otherwise: nothing, and there are dozens of companies desperately looking for partners. So far as I can tell, it's not that these companies have been getting low-ball offers, it's that they haven't been getting offers at all. Mid and Big Pharma have had no reason to rush, and indeed plenty of reason to wait. As has been discussed.

To describe this as if it is a one-actor morality play is to ignore the context, and no answers will be found that way. At least, none that have any truth to them.

NeuroInvestment